Left ventricular dysfunction – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Left ventricular dysfunction – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function https://clinicaltrials.eu/trial/a-study-of-finerenone-added-to-standard-treatment-in-children-aged-6-months-to-under-18-years-with-heart-failure-and-reduced-left-heart-pumping-function/ Wed, 29 Apr 2026 15:08:46 +0000 https://clinicaltrials.eu/trial/a-study-of-finerenone-added-to-standard-treatment-in-children-aged-6-months-to-under-18-years-with-heart-failure-and-reduced-left-heart-pumping-function/ This study is looking at heart failure with left ventricular systolic dysfunction in children and teenagers. Heart failure is a condition where the heart cannot pump blood as well as it should, and left ventricular systolic dysfunction means that the left side of the heart, which is the main pumping chamber, is not working properly. The study will test a medication called finerenone, which is also known by its code name BAY 94-8862. Some participants will receive finerenone while others will receive placebo. All participants will continue to take their regular heart failure medicines that their doctors have prescribed. The medication being tested comes in different forms including tablets and granules that can be mixed with liquid for children who cannot swallow tablets.

The purpose of the study is to see if finerenone can reduce levels of a substance in the blood called NT-proBNP, which is a marker that shows how well the heart is working. The study will also look at how safe finerenone is and how the body processes the medication. Participants in this study will be children from 6 months old up to 18 years old who have heart failure caused by various conditions such as heart defects present from birth, inherited heart muscle problems, inflammation of the heart muscle, certain muscle disorders, or other causes affecting the heart’s pumping ability. The children must already be taking standard medicines for heart failure for at least 30 days before joining the study.

During the study, participants will be assigned by chance to receive either finerenone or placebo in addition to their regular heart failure treatment. The treatment will last for 3 months, and doctors will measure various things including blood levels of NT-proBNP, potassium levels, blood pressure, kidney function, and heart function using ultrasound imaging of the heart. The study will also track any unwanted effects that occur and will monitor for serious heart-related events. Blood tests will be done to measure how much finerenone is in the body and how long it stays there. The entire study is expected to run from 2025 until the end of 2029.

]]> A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction https://clinicaltrials.eu/trial/a-study-of-finerenone-with-standard-treatment-for-children-and-young-adults-from-birth-to-18-years-with-heart-failure-and-left-ventricular-systolic-dysfunction/ Wed, 29 Apr 2026 15:08:46 +0000 https://clinicaltrials.eu/trial/a-study-of-finerenone-with-standard-treatment-for-children-and-young-adults-from-birth-to-18-years-with-heart-failure-and-left-ventricular-systolic-dysfunction/ This study looks at heart failure with left ventricular systolic dysfunction in children and young people from birth to 18 years of age. Left ventricular systolic dysfunction means that the left lower chamber of the heart, which pumps blood to the body, does not squeeze or contract as well as it should. The treatment being studied is finerenone, also known as BAY 94-8862, which will be given in addition to standard of care treatment. Finerenone comes in different forms including film coated tablets and granules for oral suspension that are taken by mouth. The purpose of this study is to show that finerenone is safe when given for a long time together with standard treatment in children with this heart condition.

This study is an extension study, which means some participants may join after completing a previous study with finerenone, while other newly enrolled infants under 6 months of age can join directly if they meet certain health requirements. During the study, participants will receive finerenone along with their regular heart failure medications. The study will monitor various safety measures including blood potassium levels, blood pressure, and kidney function, as well as checking for any unwanted effects of the treatment. The study will also measure levels of a substance called NT-proBNP in the blood, which is a marker of heart function, and will use imaging with echocardiography to see how well the heart is working.

The study will last for approximately 270 days for each participant. Throughout this time, regular visits will be scheduled to check the safety and effects of the treatment. Blood samples will be collected to measure how much finerenone is in the body. For participants using the granules for oral suspension, there will be questions about the taste and texture of this form of the medicine. The study will track any side effects or health changes that occur during treatment.

]]> Study on Vericiguat for Children with Heart Failure from Left Ventricular Systolic Dysfunction https://clinicaltrials.eu/trial/study-on-vericiguat-for-children-with-heart-failure-from-left-ventricular-systolic-dysfunction/ Wed, 29 Apr 2026 14:47:53 +0000 https://clinicaltrials.eu/trial/study-on-vericiguat-for-children-with-heart-failure-from-left-ventricular-systolic-dysfunction-2/ This clinical trial is focused on studying a condition known as Heart Failure due to a specific problem with the heart called Left Ventricular Systolic Dysfunction. This condition affects the heart’s ability to pump blood effectively. The study involves a treatment called Vericiguat, which is being tested to see how safe and tolerable it is for children with this type of heart failure. Vericiguat is available in two forms: a tablet and an oral suspension, which is a liquid form that can be swallowed.

The purpose of this study is to monitor the safety and tolerability of Vericiguat, also known by its code name MK-1242. Participants in this study will have previously been part of an earlier study and will continue to receive Vericiguat. The study will observe participants over a period to see if they experience any side effects or need to stop the treatment due to any adverse effects. The study will also look at changes in a specific heart-related protein in the blood, known as N-terminal pro-brain natriuretic peptide (NT-proBNP), which can indicate how well the heart is functioning.

Participants will take Vericiguat by mouth, either as a tablet or a liquid, for a maximum period of 108 weeks. The study aims to ensure that the treatment is safe and well-tolerated by the participants. This trial is an extension of a previous study, allowing researchers to gather more information about the long-term effects of Vericiguat in children with heart failure due to left ventricular systolic dysfunction.

]]>